Global Pneumonia Vaccines Market to reach a market size of $9.6 billion by 2025- KBV Research


Posted August 20, 2019 by kbv_research

The Global Pneumonia Vaccines Market size is expected to reach $9.6 billion by 2025, rising at a market growth of 5.1% CAGR during the forecast period.
 
According to a new report Global Pneumonia Vaccines Market, published by KBV research, The Global Pneumonia Vaccines Market size is expected to reach $9.6 billion by 2025, rising at a market growth of 5.1% CAGR during the forecast period.

The North America market dominated the Global Pneumococcal Conjugate Vaccine (PCV) Market by Region in 2018, growing at a CAGR of 2.8 % during the forecast period. The Europe market is expected to witness a CAGR of 3.6% during (2019-2025). Additionally, The Asia Pacific market is expected to witness a CAGR of 5.3% during (2019-2025).

The Prevnar 13 market dominated the Global Pneumonia Vaccines Market by Product Type in 2018, growing at a CAGR of 4.1 % during the forecast period. The Synflorix market is expected to witness a CAGR of 7.5% during (2019-2025). Additionally, The Pneumovax23 market is expected to witness highest CAGR of 8.5% during (2019-2025).

The Distribution Partner Companies market dominated the Global Pneumonia Vaccines Market by Distribution Channel in 2018, growing at a CAGR of 4.3 % during the forecast period. The Non-Governmental Organizations (NGO) market is expected to witness a CAGR of 6% during (2019-2025).

Full Report: https://www.kbvresearch.com/pneumonia-vaccines-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Glaxosmithkline Plc. (GSK), LG Corporation, Panacea Biotec Limited, Pfizer, Inc., Pnuvax Incorporated, Poonawalla Investments & Industries Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd., SK Holdings Co., Ltd., Walvax Biotechnology Co., Ltd. and MERCK & CO., Inc.

Global Pneumonia Vaccines Market Segmentation

By Vaccine Type

Pneumococcal conjugate vaccine (PCV)
Pneumococcal polysaccharide vaccine (PPSV/PPV)

By Product Type

Prevnar 13
Synflorix
Pneumovax23

By Sector

Public sector
Private sector

By Distribution Channel

Distribution partner companies
Non-governmental Organizations (NGO)
Government Authorities

By Geography

North America

US
Canada
Mexico
Rest of North America

Europe

Germany
UK
France
Russia
Spain
Italy
Rest of Europe

Asia Pacific

China
Japan
India
South Korea
Singapore
Malaysia
Rest of Asia Pacific

LAMEA

Brazil
Argentina
UAE
Saudi Arabia
South Africa
Nigeria
Rest of LAMEA

Companies Profiled

Glaxosmithkline Plc. (GSK)
LG Corporation
Panacea Biotec Limited
Pfizer, Inc.
Pnuvax Incorporated
Poonawalla Investments & Industries Pvt. Ltd.
Shenzhen Kangtai Biological Products Co., Ltd.
SK Holdings Co., Ltd.
Walvax Biotechnology Co., Ltd.
Merck & Co., Inc.

Unique Offerings from KBV Research

Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free

Pneumonia Vaccines Market Related Reports:

North America Market
Europe Market
Asia Pacific Market
LAMEA Market
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By KBV Research
Phone 6466616066
Business Address 244 Fifth Avenue, Suite 1407 New York, N.Y. 10001 United States (U.S)
Country United States
Categories Medical
Tags kbv research , pneumonia vaccines , pneumonia vaccines market , pneumonia vaccines market analysis , pneumonia vaccines market growth , pneumonia vaccines market size
Last Updated August 20, 2019